Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Other Non Operating Income (2017 - 2020)

Outlook Therapeutics (OTLK) has disclosed Other Non Operating Income for 3 consecutive years, with $6.2 million as the latest value for Q2 2020.

  • On a quarterly basis, Other Non Operating Income rose 1554.92% to $6.2 million in Q2 2020 year-over-year; TTM through Jun 2020 was -$1.9 million, a 212.28% decrease, with the full-year FY2023 number at -$577659.0, up 43.67% from a year prior.
  • Other Non Operating Income was $6.2 million for Q2 2020 at Outlook Therapeutics, up from -$8.1 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $6.2 million in Q2 2020 to a low of -$8.1 million in Q4 2019.
  • A 3-year average of -$751177.8 and a median of -$423686.0 in 2019 define the central range for Other Non Operating Income.
  • Biggest YoY gain for Other Non Operating Income was 1554.92% in 2020; the steepest drop was 1554.92% in 2020.
  • Outlook Therapeutics' Other Non Operating Income stood at -$1.3 million in 2017, then plummeted by 543.63% to -$8.1 million in 2019, then surged by 176.47% to $6.2 million in 2020.
  • Per Business Quant, the three most recent readings for OTLK's Other Non Operating Income are $6.2 million (Q2 2020), -$8.1 million (Q4 2019), and -$423686.0 (Q2 2019).